1-6 of 6
Dave Yamauchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Free
Amrita Y. Krishnan, MD, Joycelynne Palmer, PhD, Auayporn P. Nademanee, MD, Robert Chen, Leslie L. Popplewell, MD, Nicole Tsai, MS, James F. Sanchez, PhD, Jennifer Simpson, Ricardo Spielberger, MD, Dave Yamauchi, MD, Stephen J. Forman, MD
Journal: Blood
Blood (2015) 126 (23): 3179.
https://doi.org/10.1182/blood.V126.23.3179.3179
Published: 2015
Journal Articles

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Free
Amrita Krishnan, M.D., Joycelynne Palmer, PhD, Auayporn Nademanee, M.D., Andrew Raubitschek, MD, Dave Yamauchi, Neil Martin Kogut, MD, Laura Federico, Nicole Tsai, Stephen Forman, M.D.
Journal: Blood
Blood (2010) 116 (21): 32.
https://doi.org/10.1182/blood.V116.21.32.32
Published: 2010
Journal Articles

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).

Free
Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Auayporn P. Nademanee, MD, N. Kogut, MD, Leslie Popplewell, MD, Ni-Chun Tsai, Joycelynne Palmer, PhD, Jennifer Simpson, Laura Federico, Dave Yamauchi, MD, Stephen J. Forman, MD
Journal: Blood
Blood (2009) 114 (22): 2323.
https://doi.org/10.1182/blood.V114.22.2323.2323
Published: 2009
Journal Articles

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Free
Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Auayporn P. Nademanee, MD, N. Kogut, MD, Dave Yamauchi, MD, Leslie Popplewell, MD, Laura Federico, Jennifer Simpson, Ni-Chun Tsai, Stephen J Forman, MD
Journal: Blood
Blood (2009) 114 (22): 3423.
https://doi.org/10.1182/blood.V114.22.3423.3423
Published: 2009
Journal Articles

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Free
Auayporn P. Nademanee, MD, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Dave Yamauchi, MD, Maria Delioukina, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Eileen Smith, MD, Anthony Stein, MD, Neil Kogut, MD, Margaret O'Donnell, MD, Stephen J Forman, MD
Journal: Blood
Blood (2009) 114 (22): 3357.
https://doi.org/10.1182/blood.V114.22.3357.3357
Published: 2009
Journal Articles

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Free
Clinical Trials & Observations
Auayporn Nademanee, Stephen Forman, Arturo Molina, Henry Fung, David Smith, Andy Dagis, Cheuk Kwok, Dave Yamauchi, Anne-Line Anderson, Peter Falk, Amrita Krishnan, Mark Kirschbaum, Neil Kogut, Ryotaro Nakamura, Margaret O'Donnell, Pablo Parker, Leslie Popplewell, Vinod Pullarkat, Roberto Rodriguez, Firoozeh Sahebi, Eileen Smith, David Snyder, Anthony Stein, Ricardo Spielberger, Jasmine Zain, Christine White, Andrew Raubitschek
Journal: Blood
Blood (2005) 106 (8): 2896–2902.
https://doi.org/10.1182/blood-2005-03-1310
Published: 2005